It is likely that needle therapy affects biochemical markers associated with obesity, including obesity-related peptides (e.g., leptin and ghrelin), insulin resistance, and inflammatory markers. The gene discussed is GHRL; the disease is obesity due to melanocortin 4 receptor deficiency.